CD22CART infusion

DRUG2 trials

Sponsors

Stanford University

Conditions

Acute Lymphoblastic LeukemiaBurkitt LymphomaFollicular LymphomaHairy Cell LeukemiaLarge B-cell LymphomaLeukemiaLymphoplasmacytic LymphomaMantle Cell Lymphoma

Phase 1

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

RecruitingNCT06340737

Stanford UniversityBurkitt Lymphoma, Follicular Lymphoma, Hairy Cell Leukemia +5

Start: 2024-03-29End: 2031-04-01Target: 148Updated: 2026-08-12

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

RecruitingNCT06408194

Stanford UniversityAcute Lymphoblastic Leukemia, Leukemia

Start: 2024-05-13End: 2027-02-01Target: 28Updated: 2026-09-01

Related Papers

CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity

Blood2025-11-03

CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma

Blood2024-11-052 citations